Schott Kaisha, a leading manufacturer of tubular glass primary packaging in India, and Vanrx Pharmasystems, a company making the most technologically advanced sterile filling solutions for pharmaceutical industry, jointly announced compatibility between Schott’s ready-to-use nested syringes, cartridges and stoppers, and Vanrx’s Aseptic Filling Workcells.

Both companies have worked together to confirm these containers and closures as product sets as part of the Matrix Alliance, an industry initiative of leading packaging and component suppliers which aims to providing pre-validated container-closure solutions to work on Vanrx’s robotic aseptic filling machines. The alliance was created because next-generation drugs require highly aligned manufacturing processes and packaging solutions.

Product sets are fully commercially available and ready-to-use, with closure integrity performance results available from Schott and Vanrx. Using these product sets, pharmaceutical companies have the assurance that the combination will function as a high-performance primary packaging system for sterile injectables.  Additionally, all elements of the set have been proven for compatibility and machinability with Vanrx aseptic filling systems.

Companies can move drug products to market faster, by establishing flexible manufacturing operations using pre-sterilized, nested ready-to-use containers and closures in combination with Vanrx’s robotic aseptic filling systems. Product set combinations are available in Schott Kaisha 1 mL long syringes with Schott nested syringe stoppers in both 100 and 160 unit per nest configurations, and Schott 3 mL cartridges with its nested cartridge stoppers in a 100 unit per nest configuration. These products are certified to work with Vanrx’s SA25 Aseptic Filling Workcell.

Rishad Dadachanji, Schott’s director said, “As ready-to-use solutions gain traction in the market, we are determined to create a large portfolio consisting of all standard sizes, commercially available to our customers. Apart from being able to offer only the packaging, Vanrx and Schott have taken the initiative to have our components validated for compatibility and machinability with the Vanrx system. This pre-validated combination of a single machine and broad product portfolio allows us to provide tested and reliable solutions to our common customers, enabling them with the flexibility to fill multiple sizes and a variety of products with ease.”

Vanrx’s vice president of marketing Greg Speakman said, “Vanrx and Schott Kaisha have seen the how pharmaceutical companies are shifting toward building flexible manufacturing operations. Schott and Vanrx are helping bring new products to market faster, benefiting the patient and our customers’ ability to respond to uncertain market conditions.”